Literature DB >> 8277182

Persistence of cell-mediated and humoral immune responses in healthy children immunized with live attenuated varicella vaccine.

B Watson1, R Gupta, T Randall, S Starr.   

Abstract

Two hundred fourteen healthy seronegative children immunized with various doses of Oka/Merck varicella vaccine were studied for persistence of varicella-zoster virus (VZV)-specific lymphocyte proliferation and antibodies to VZV as determined by a glycoprotein (gp) ELISA. Of the 140 vaccinees tested for VZV-specific lymphocyte proliferation, 94% had positive responses, with a mean stimulation index of 8.9 (range, 3.0-44.6). Of 214 tested by gpELISA, 95% were positive for up to 6 years after immunization; the geometric mean titer was 30.2 (range, 1.3-3510.0). Of 122 individuals tested both by ELISA and for VZV-specific lymphocyte proliferation, 91% had persistence of both responses. Persistence of cellular and humoral immune responses in a large percentage of vaccinees for up to 6 years after immunization with Oka/Merck varicella vaccine suggests that protection against severe varicella is likely to be similarly long-lasting.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8277182     DOI: 10.1093/infdis/169.1.197

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

Review 1.  Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults.

Authors:  Kristine Macartney; Anita Heywood; Peter McIntyre
Journal:  Cochrane Database Syst Rev       Date:  2014-06-23

2.  Use of a reformulated Oka strain varicella vaccine (SmithKline Beecham Biologicals/Oka) in healthy children.

Authors:  A Y Tan; C J Connett; G J Connett; S C Quek; H K Yap; F Meurice; B W Lee
Journal:  Eur J Pediatr       Date:  1996-08       Impact factor: 3.183

3.  Immunisation against varicella in end stage and pre-end stage renal failure. Trans-Pennine Paediatric Nephrology Study Group.

Authors:  N J Webb; M M Fitzpatrick; D A Hughes; T J Brocklebank; B A Judd; M A Lewis; R J Postlethwaite; P A Smith; G Corbitt
Journal:  Arch Dis Child       Date:  2000-02       Impact factor: 3.791

4.  Immunisation against chickenpox.

Authors:  L F Ross; J D Lantos
Journal:  BMJ       Date:  1995-01-07

5.  Advances in immunization.

Authors:  D L Stulberg
Journal:  West J Med       Date:  1995-07

Review 6.  Varicella-zoster virus.

Authors:  A M Arvin
Journal:  Clin Microbiol Rev       Date:  1996-07       Impact factor: 26.132

7.  Varicella vaccination in children with lymphoma and solid tumours.

Authors:  S Emir; M Büyükpamukçu; V Köseoğlu; G Hasçelik; C Akyüz; T Kutluk; A Varan
Journal:  Postgrad Med J       Date:  2006-11       Impact factor: 2.401

Review 8.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

9.  Human anti-varicella-zoster virus (VZV) recombinant monoclonal antibody produced after Zostavax immunization recognizes the gH/gL complex and neutralizes VZV infection.

Authors:  Marius Birlea; Gregory P Owens; Emily M Eshleman; Alanna Ritchie; Igor Traktinskiy; Nathan Bos; Scott Seitz; Yevgeniy Azarkh; Ravi Mahalingam; Don Gilden; Randall J Cohrs
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

10.  Evaluation of a commercial glycoprotein enzyme-linked immunosorbent assay for measuring vaccine immunity to varicella.

Authors:  Yun Hwa Kim; Ji Young Hwang; Hye Min Shim; Eunsil Lee; Songyong Park; Hosun Park
Journal:  Yonsei Med J       Date:  2014-03       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.